CML Treated With Bosutinib After Relapse
NCT02445742
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Chronic Myeloblastic Leukaemia
Interventions
DRUG:
Bosutinib
Sponsor
PETHEMA Foundation